We are live on ! Find out more
DYN icon

Dyne Therapeutics

69 hedge funds and large institutions have $615M invested in Dyne Therapeutics in 2020 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 13

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

38% more funds holding

Funds holding: 5069 (+19)

11% more capital invested

Capital invested by funds: $554M → $615M (+$61.1M)

3.95% more ownership

Funds ownership: 60.52%64.47% (+4%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
69
Holders Change
+19
Holders Change %
+38%
% of All Funds
1.22%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
32
Increased
13
Reduced
9
Closed
13
Calls
Puts
Net Calls
Net Calls Change

DYN Hedge Fund Activity: Q4 2020 in Review

69 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q4 2020, worth a combined $615M — up 11% from $554M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new DYN positions and 13 closed out — a net gain of 19 holders — while 13 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $14.5M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $9.58M sold.

  • 69 institutional investors held Dyne Therapeutics (DYN) as of Q4 2020, up from 50 in Q3 2020.
  • Funds reported $615M of Dyne Therapeutics stock for Q4 2020, up 11% quarter-over-quarter.
  • 32 funds opened new Dyne Therapeutics positions in Q4 2020 and 13 closed out, a net change of +19 holders.
  • The largest Dyne Therapeutics buyer in Q4 2020 was BlackRock, an estimated $14.5M added.
  • The largest Dyne Therapeutics seller in Q4 2020 was Sectoral Asset Management, an estimated $9.58M sold.

Based on aggregated 13F filings for Q4 2020.